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ABSTRACT 
Introduction: Asthma is a chronic inflammatory airway disease. It occurs in a “severe” form in 
about 8-10% of asthmatic patients. In the last decade the development of biological drugs (e.g. 
monoclonal antibodies) allowed to efficiently approach severe asthma. The current therapeutic 
targets available are mainly those related to TH2 inflammation. 
Areas covered: The main pharmacokinetic and pharmacodynamic characteristics of the monoclonal 
antibodies against IL-5, IL-5Ra, IL4-IL13 and IgE, that are currently marketed or understood for 
severe asthma are discussed in this paper.  
Expert opinion: The currently available biological drugs represent an excellent therapeutic add-on 
to traditional drugs, especially in replacing systemic corticosteroid therapies. The different 
pharmacokinetic and pharmacodynamic characteristics of the drugs, despite sometime sharing the 
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same target, would allow a better personalization of the therapy, tailoring the treatment to the 
characteristics of the patient.  
Key Words: severe asthma, pharmacokinetic, pharmacodynamics, monoclonal antibodies, 
biological drugs, precision medicine, personalized medicine 
 
ABBREVIATIONS: 
ADCC: antibody-dependent cell-mediated cytotoxicity 
AUC∞: area under the serum concentration-time curve 
ICS: inhaled corticosteroids 
Cmax: Maximum plasma concentrations 
IV: intravenous 
LABA : long-acting beta2-agonists 
mAB : monoclonal antibody 
PD: pharmacodynamic  
PK:  pharmacokinetic  
SC: subcutaneous 
TH: T Helper lymphocyte   
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Article highlights:  
1. Monoclonal antibodies are an efficient therapy in patients with severe asthma 
2. Biological drugs currently marketable can be used in patients with an allergic or an 
eosinophilic phenotype of asthma 
3. The pharmacokinetic and pharmacodynamic aspect of these drugs makes them different from 
each other despite, in some cases, the biological target is the same 
4. The point of inoculum of these drugs modifies the pharmacokinetics mechanisms, therefore it 
is necessary to use the one suggested by clinical trials to guarantee a correct absorption 
5. Although these drugs have different routes of administration, they have proved equally 
effective, despite this modifying PK and PD  
 
1. INTRODUCTION 
Asthma is a chronic airways disease, with high incidence and prevalence, usually sustained by a 
bronchial inflammatory process. It is estimated that about 235 million of people suffer from asthma, 
and the prevalence of this disease is still rising worldwide [1,2]. About 10% of asthmatic subjects  
have a severe uncontrolled form of the disease [3]. These patients, according to ATS/ERS 
guidelines, though receiving the highest dose of inhaled therapies, principally based on inhaled 
corticosteroids (ICS) and long-acting beta2-agonists (LABA), are not controlled and must take 
other drugs to try to control the disease [4]. People with uncontrolled severe asthma have a higher 
risk of exacerbations, morbidity and mortality, not to mention the direct and indirect economic 
burden on the healthcare system [5]. In recent years some biological drugs have been developed to 
provide a therapeutic response to a part of patients who do not respond adequately to traditional 
therapies. Nowadays these drugs are mainly targeted to those patients with prevalent T Helper 
(TH)2-type inflammation [6,7], that is, for historical and cultural reasons, the better known.  
2. THERAPEUTIC TARGETS OF mABs 
Currently many biological agents with different biological targets are under clinical 
experimentation, but only drugs directed on IgE and eosinophils have been marketed. Both 
mechanisms represent different faces of the same type of asthma, namely the TH2-dominant 
phenotype. Frequently, type 2-immunity is activated by the exposure to allergens and it develops by 
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the differentiation of naïve T CD4+ cells, associated with IgE production, increase in peripheral 
eosinophils and allergen-triggered mast cell activation. The principal cytokines involved in type 2 
immune response are interleukin (IL) 4, IL-5, IL-9, and IL-13 [8-10]. Since the role of those 
cytokines/receptors are well recognized, these molecules have been the main  therapeutic targets. 
3. OMALIZUMAB ( Xolair ™,anti IgE) 
The oldest, and therefore deeply studied biological drug in the field of severe asthma is 
omalizumab. It’s a recombinant humanized antibody with a human framework and complementary-
determining region obtained from an anti-IgE murine antibody [11]. It is derived from recombinant 
DNA which selectively binds to immunoglobulin E (IgE human). 
3.1) PHARMACOKINETIC (PK) CHARACTERISTICS OF OMALIZUMAB 
Omalizumab is marketed in pre-filled syringes with variable dosages and frequency of 
administration, depending on weight and IgE levels [12]. The absorption of the anti-IgE molecule 
results to be rather slow, with a peak of absorption within 7-8 days after administration and an 
average bioavailability of about 62% [13]. The pharmacokinetics of omalizumab results to be linear 
at doses above 0.5 mg/Kg. With the subsequent administrations, the area under the serum 
concentration-time curve (AUC) of omalizumab increases. Once a steady state has been reached the 
AUC after 14 days results to be greater up to six times compared to the first administration [14]. 
Specific studies on severe asthmatic people have shown that omalizumab have an apparent volume 
of distribution of about 78 ± 32 mL/Kg [15]. Although omalizumab form complexes with IgE, it has 
been observed that these do not exceed the molecular weight of one million Daltons neither in vitro 
nor in vivo. The clearance of the omalizumab involves IgG clearance processes as well as through 
specific bonds and formation of complexes with its target ligand, the IgE [15]. The hepatic 
elimination of IgG includes degradation in the reticuloendothelial system and endothelial cells. 
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Unchanged IgG is also excreted into the biliary fluid. In asthmatic patients it was shown an average 
elimination half-life of about 26 days, with a clearance of 2.4 ± 1.1 mL/Kg/day [13,15,16].  
 
3.2) PHARMADYNAMIC (PD) CHARACTERISTICS OF OMALIZUMAB 
The administration of Omalizumab decreases  the concentration of free IgE level, thus preventing 
the binding of IgE to high (FcRI) and low-affinity (FcRII/CD23) receptors, interrupting the 
activation of mast cells and basophils degranulation [11]. Once linked to IgE, Omalizumab, creates 
small sizes immune complexes, that turn out to be soluble, biologically inert, unable to fix the 
complement and to precipitate in the kidney [11]. Furthermore Omalizumab, due to the its action 
reduction of free IgE, promotes a down-regulation of FcRI on mast cells and basophils, leading to 
a reduction in responsivity of these cells to antigens [17]. Several studies demonstrated that 
basophils histamine release, in people traded with omalizumab, decrease of about 90% compared 
with non-treated patients [18]. Clinical studies demonstrated that serum levels of free IgE decreased 
in a dose-dependent manner within one hour of the first administration and remained stable between 
doses [19]. 
4. MEPOLIZUMAB (Nucala ™, anti IL-5) 
  Mepolizumab is a humanized mAb belonging to the IgG1/k class whose target is IL-5, a cytokine 
with a crucial role in eosinophils development, maturation and action [20]. This molecule is 
indicated in subjects with severe uncontrolled asthma and high blood eosinophils levels. The first 
route of administration  in clinical trials was the intravenous one, with different doses (75 mg, 250 
mg and 750 mg). Subsequently the subcutaneous (SC) administration was chosen at the fix dose of 
100 mg, regardless of weight or other factors, due to the fact that endpoints obtained with SC and 
intravenous (IV) administration were overlapping [21]. As the subcutaneous administration has 
proved to be as effective as the intravenous one, due to a greater simplicity of use and a less 
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invasive, the drug has been commercialized in this formulation. Furthermore, in the case of 
mepolizumab, the subcutaneous formulation also proved to be safer with lower side effects than the 
EV [22].  
4.1) PHARMACOKINETIC (PK) CHARACTERISTICS OF MEPOLIZUMAB 
The pharmacokinetic of Mepolzumab was assessed in various studies:  animal models,  
humans, healthy and  asthmatic patients. We summarize herein the main studies on human model 
both in healthy asthmatic subjects. 
One of the main pharmacokinetic trial, was conducted in an open-label, single-dose, randomized, 
parallel group  12-week study (study SB-240563/018) [23], where 60 healthy people were enrolled 
and treated. Different arms of treatment were planned:  one received 250 intravenously as a 30-
minute infusion (n = 12), other groups received the drug subcutaneously in three different body site 
(abdomen, arm or thigh; n = 12 each site) and the last group received an intramuscular injection in 
the lateral thigh (n = 12). The bioavailability of mepolizumab, through SC route of administration 
resulted 64% in the abdomen, 75% in the arm and 71% on thigh, as compared with the one of the 
intramuscular route that was 81% [2,24].  Maximum plasma concentrations (Cmax) was observed 
after 0.5-4.8 hours from the beginning of the infusion. Although the time taken to reach the Cmax 
was longer (2-14 days) in the SC than the IV administration, mepolizumab was found to be equally 
well absorbed in both routes of administrations. Consistently with what is known for endogenous 
IgG1 antibodies in humans [25,26], the half-life of mepolizumab was approximately 20 days, 
regardless of the route of administration [27]. 
Several trials are also available, conducted in asthmatic patients. A first study was a multicentre, 
double-blind, randomized, placebo-controlled, dose escalation study, performed on patients (n = 38) 
with a mild atopic asthma, where mepolizumab was administrated intravenously one time at the 
dose of 0.05 mg/kg, 0.5 mg/kg, 2.5 mg/kg, or 10 mg/kg, than compared with placebo. After the 
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administration, the  concentration of Mepolizumab decreased with a mean early t1/2 of about two 
days. The terminal t1/2 was documented after about 20 days (14-30 days). The observations done on 
Cmax and AUC suggested a linear pharmacokinetic profile of the drug [28]. Pouliquen and 
colleagues described the results of a multi-center, randomized, open-label, parallel-group, repeat-
dose study where mepolizumab was administered to 70 subjects (66 completed) with asthma and 
blood eosinophils count of at least 300 cells/µL. Three SC dose of drug (12.5, 125, and 250 mg) 
were administered subcutaneously and compared to 75 mg intravenously [29]. In this trial the 
terminal half-life estimated was of 22 days for SC and 28 for IV administration. Regarding tmax , the 
median time was assessed at 6-8 days after SC dosing compared with 0.5 hours in IV dosing. 
Bioavailability was found to be the same for all SC dosage (74%). The pharmacokinetic profiles 
resulted to be  more variable at the dose of 12.5 mg than in the other groups. The SC formulation 
was also evaluated in a trial where 250 mg was administered for three times. Doses 1 and 2 were 
given 6 weeks apart; dose 3 was given 2 weeks after dose 2. Due to the known half-life of about 20 
days, plasma accumulation was observed after third dose. The recorded AUC and Cmax resulted 
higher after dose 3 than dose 1 (65% and 80%) [30]. Further  data were provided  by Ortega et al. 
where mepolizumab was given subcutaneously at different sites, and compared with intramuscular 
and IV route. The best SC bioavailability was  recorded in arm 75% (66–86), AUC resulted 1,238 
(±228) mg d/mL. The half-life was protracted, in a range of  11 to 26 days and  independent of 
dosing route and clearance from 1.9 to 3.3 mL/day/kg [31]. 
 
 
4.2) PHARMACODYNAMIC (PD) CHARACTERISTICS OF MEPOLIZUMAB 
 
As it happened for pharmacokinetics studies,  also pharmacodynamic one were performed in 
healthy and asthmatic patients. In the above mentioned trial [23]  about 60 people treated with 
mepolizumab at different dose and different administration routes, the peripheral blood eosinophils 
count described a substantial decrease of at least 50% from baseline [23]. In mild-moderate 
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asthmatic patients, Leckie and colleagues described the results with an  administration of 2.5 and 10 
mg/Kg intravenously. The blood eosinophil count decreased by 73% from baseline on 8th day, and 
by 87% on day 29 in patients treated with 10 mg/Kg, as compared to  32% and 34% in the placebo 
arm [28]. People treated with 10 mg/Kg also showed a  reduction in blood (p<0.001) and sputum 
(p<0.01) eosinophils count post an allergen challenge, compared with placebo. Less apparent results 
were observed with 2.5 mg/Kg. A subsequent double-blind, randomized, placebo-controlled  study, 
involved the administration of a single IV dose of 0.5mg/kg (n = 4), 2.5mg/kg (n = 4) or 10mg/kg 
(n = 4), or placebo (n = 6). This study confirmed  a reduction of blood eosinophils count higher in 
people treated with mepolizumab (max decrease estimated 85%; IC50 of 0.45 mg/mL) [32]. 
Pouliquen REF also confirmed the reduction of blood eosinophils with all   dosages and routes of 
administration, although the 12.5 mg dose was less effective. Overall, a significant and prompt 
reduction in peripheral eosinophils appeared since the third day, with a marginal reduction between 
7 and the end of the study day (84 day) [29]. Eosinophils levels decreased not only in blood but also 
in sputum, starting from day 7 to the end of treatment period (day 84) in all groups, with the largest 
decreases in the SC 125 and 250 mg. Despite the effect of mepolizumab on peripheral eosinophil 
count is well ascertained, what happens in other organs is not well defined. A reduction has been 
observed both in bronchial mucosa (biopsies), where a median decrease of 55% from baseline was 
recorded at the ninth week of EV administration (p = 0.009 vs placebo), and in bone marrow 
samples where eosinophils showed a median reduction of 52%,  again at the ninth week of 
treatment (p = 0.003 vs placebo). On the other hand, no statistically significant decrease in 
eosinophils could be demonstrated in bronchoalveolar lavage fluid (BALF) in patients treated with 
mepolizumab compared with placebo group (p=0.4), despite the median reduction from baseline 
was 79% [33].  
 
5. BENRALIZUMAB (Fasenra ™ anti IL-5Ra) 
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Benralizumab is a humanized mAB of the IgG1/k class which binds D1 domain of  IL-5Ra, or 
CD125 [34,35] that is expressed on eosinophils and basophils  surface [20, 36]. This molecule is not 
fucosylated: this increases its affinity for the FcγRIIIa receptor, and achieves an antibody-dependent 
cell-mediated cytotoxicity (ADCC) [20,37]. Similarly to mepolizumab, also benralizumab the 
eligible patients are severe asthmatic people with high levels of eosinophils (> 300 cell/γL).  
5.1) PHARMACOKINETIC (PK) CHARACTERISTICS OF BENRALIZUMAB 
The PK characteristics of benralizumab was firstly investigated by Busse and colleagues, in 
a  phase I, multicentre, open-label, sequential dose-escalation study, where the drug was 
administered in mild atopic asthmatic patients (age 18-45 years). The drug was given according to a 
dose-incremental design:  cohort 1, 0.03 mg/kg; cohort 2, 0.1 mg/kg; cohort 3, 0.3 mg/kg; cohort 4, 
1 mg/kg; and cohort 5, 3 mg/kg. Two additional cohorts were also added (cohort 6, 0.003 mg/kg; 
cohort 7, 0.0003 mg/kg), with the aim to identify the minimum effective dose. The results about 
mean Cmax, at the doses of 0.03 and 3 mg/kg resulted approximatively dose-proportional (1 mg/mL 
to 82 mg/mL), as well as the AUC∞  (5 mg*d/mL to 775 mg*d/mL) [38]. As for  other mAbs, also 
benralizumab, in its clearance, behaves like typical human IgG antibodies, with a mean elimination 
half-life of around 18 day, at the doses of 0.03 and 3 mg/kg. The data held by the researchers also 
showed a clearance of about 4 mL/kg/day, with a faster clearance and a shorter half-life in 0.03 
mg/Kg group. The large volume of distribution, established between (52– 93 mL/Kg), suggested a 
possible drug binding to receptors IL-5Ra expressed by blood cells and/or its penetration into the 
extravascular tissue [34-38]. Pharmacokinetic effects observed in a Phase II safety study, where 
benralizumab was administered at three different doses (25, 100 and 200 mg) subcutaneously, 
showed a Cmax  between 1.2 and 14 μg/mL and an AUC∞ between 0.12 ± 0.071 and 1.2 ± 0.11 mg 
day/mL [40,41].  
A pooled analysis took into consideration six different studies to characterize pharmacokinetic and 
pharmacodynamics characteristics of benralizumab [42]. The resulting pharmacokinetic model was 
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a two-compartment model with first-order elimination from the central compartment and with a 
first-order absorption from the dosing site regarding the SC administration [39]. The calculated 
mean systemic clearance was 0.321 L/day, which turned out to be within the therapeutic range of 
mAbs [43]. The estimated volume of distribution of the central and the peripheral compartments 
results 3.16 and 2.83 L. In SC administration route the absorption of benralizumab results slow, 
with a constant rate of 0.252/day with a mean absorption time of 3.97 days. Bioavailability turned 
out to be 52.6% [42]. 
5.2) PHARMACODYNAMIC (PD) CHARACTERISTICS OF BENRALIZUMAB 
 
In the trial  by Busse et al. benralizumab reduced the blood eosinophil counts,  at dosages higher 
than 0.3 mg/kg within 24 hours after the administration. The reduction of eosinophil count  
persisted for at least 12 weeks [38]. In the mentioned phase II safety trial peripheral blood 
eosinophils count was reduced in all active groups starting from the seventh day, and the reduction 
was maintained for at least 161 days, this  ensuring an acceptable security profile [40,41]. The 
effect of benralizumab on airways eosinophil population was evaluated in a Phase I study, assessing  
sputum, bone marrow and peripheral samples. The trial involved mild-to-moderate asthmatic people 
with sputum eosinophilia higher than 2.5% despite ICS treatment. The study design involved a 
single IV administration of 1 mg/Kg benralizumab or placebo (cohort 1) or three monthly SC doses 
of benralizumab 100 or 200 mg or placebo every 28 days (cohort 2). Both in the IV or SC 
administration airway mucosa eosinophil count was reduced, the median decrease from baseline 
was respectively 61.9% and 95.8%, and 18.7% and 89.9% in sputum sample. Furthermore people 
treated with benralizumab had a significant suppression of peripheral and bone marrow eosinophils. 
A similar observation was reported for basophils presenting IL-5Ra [44].  
6. RESLIZUMAB (anti IL-5) 
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Reslizumab is an anti-IL-5 mAb, differently by the other anti IL-5 it belongs to the IgG4/k class, and 
it is prescribed in asthmatic patients with eosinophilic disorders [20]. Its formulation is only 
intravenous and weight-adjusted. Clinical trials where reslizumab was administered subcutaneously 
did not reach primary endpoint (exacerbations and OCS sparing) so IV administration route is the 
only available, at the moment (NCT02452190, NCT02501629) [45]. This route and the 
characteristics of product permit to weight-adjust the dose of drug as detailed below. 
6.1) PHARMACOKINETIC (PK) CHARACTERISTICS OF RESLIZUMAB 
The pharmacokinetic properties of reslizumab were measured in a trial with three groups of 
patients, healthy (n = 130), asthmatic (n = 438) and with nasal polyps (n = 236), with I.V 3.0 mg/kg 
of the drug. After infusion, the peak of drug concentration in serum was assessed, and resulted  to 
decline in a biphasic manner. The calculated volume of distribution, settled in above 5 L, suggests a 
little extravascular distribution of the drug. AUC was calculated in 27.2 to 33.1 mg·h/mL. 
Reslizumab shows a clearance of about 7 mL/h, resulting in a linear and non-target mediate 
mechanism. The estimated half-life of reslizumab is 24 days. Usually, liver and kidney are not 
directly involved in the degradation/excretion of mAbs, thus it is unlikely that liver or kidney failure 
could modify the PK of the drug, and no dosage adjustment is required [46,48]. 
 
6.2) PHARMACODINAMIC (PD) CHARACTERISTICS OF RESLIZUMAB 
The in vitro studies showed that reslizumab has a great affinity for IL-5 (Kd = 20 pmol/l)  
that it efficiently inhibits the binding of IL-5 to Ba/F3 cells (IC50 = 0.5 nmol/l), and it is also able 
to block the proliferation of human erythroleukemic TF-1 cells mediated by IL-5 [49]. The 
biological inhibition of IL-5 is consequent to the binding of the drug to the small region ERRR 
(glutamic acid, arginine, arginine, arginine) [50]. In animal model trials on guinea pigs, sensitized 
with ovalbumin, reslizumab at doses of 0.03 and 0.3 mg/kg administered intraperitoneally, was 
shown to suppress the airway hyperactivity, in concomitance with a reduction of pulmonary 
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eosinophilia [46]. The administration of 0.3 mg/kg of reslizumab in severe asthmatic patients with 
persistent symptoms, induced a reduction in blood eosinophils count ranging between 52.3% at 48 
hours of administration to 18.9% after 30 days [51]. Increasing the dosage to 1.0 mg/kg eosinophils 
reduction the effect was  more pronounced and higher up to day 30. Thus, Reslizumab was able to 
reduce eosinophil count in blood but also in sputum. A recent study, where reslizumab (3.0 mg/kg), 
after a 12 months of wash out period, was administered to 10 prednisone-dependent asthmatics, 
with previous failure of mepolizumab. In this study Reslizumab decreased both sputum by 91.2% 
(P = 0.003) and blood eosinophils by 87.4% (P = 0.004) as compared to placebo. In this trial, out of 
10 of patients with persistent high eosinophils level despite mepolizumab, 6 achieved a <3% 
reduction with reslizumab [52]. 
(Table 1) 
7. DUPILUMAB 
Dupilumab is a fully humanized anti IL-4 receptor α monoclonal antibody, able to blocks both IL-4 
and IL-13 [53]. The studied and next to marketing route of administration is the subcutaneous one, 
with the dose of 300 mg (150 mg/ml) every two weeks. PK and PD data about this antibody have 
been studied more in the subject with atopic dermatitis (for which the drug is already on the market) 
than the one with asthma. 
7.1) PHARMACOKINETIC (PK) CHARACTERISTICS OF DUPILUMAB 
After a single administration of dupilumab (SC), at the dose of 75-600 mg, Tmax recorded was 
3-7 days with a bioavailability of 64%. The observed primarily distribution of dupilumab in 
vascular system allow to calculate a volume of distribution of about 4.6L. The mean ±SD 
steady-state trough concentrations ranged from 73.3±40.0 mcg/mL to 79.9±41.4 mcg/mL for 
300 mg dose. Dupilumab, at higher concentrations is eliminated principally thought a non-
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saturable proteolytic pathway, instead at low concentrations by  a non-linear saturable IL-4R α 
target-mediated system [54]. 
 
7.2) PHARMACODINAMIC (PD) CHARACTERISTICS OF DUPILUMAB 
 
In clinical trials, dupilumab has been able to reduce concentrations of type 2 immunity biomarkers, 
such as thymus and activation-regulated chemokine (TARC/CCL17) [54]. The action of dupilumab 
allow also to reduce fractional exhaled nitric oxide (FeNO) and circulating concentrations of 
eotaxin-3, allergen specific IgE, TARC, and periostin in asthma subjects in about 2 weeks, and total 
IgE concentration but in a longer time, with a median percent reduction from baseline in total IgE 
concentrations of 52% at Week 24 [55] and 70% at Week 52 [56]. For FeNO, the mean percent 
reduction from baseline at Week 2 was 35% [55] and 24% [56].  
8. CONCLUSIONS 
The development and marketing of biological agents as therapeutic add-on in severe asthma  
allowed to provide a clinical and therapeutic advancement for patients with uncontrolled asthma. 
Clinical trials has proved that all these drugs, though through different mechanisms, have been 
shown to have a good profile of effectiveness and safety [21,57-70]. (Table 2) 
In the context of anti IL-5 drugs, and TH2-high asthma, eosinophils maintain a central role in the 
pathogenesis of the disease. Certainly, the peripheral differential blood count is the most simple and 
feasible parameter to decide the prescription status of the anti-IL5 drugs. Nonetheless, it should be 
remembered that eosinophils are mainly marginated in specific organs (i.e. lungs), where they exert 
their biological action. Therefore it would be correct to evaluate the effect of drugs also at this level, 
particularly in low/not responder patients. Indeed in the above mentioned manuscript by Mukherjee, 
despite the low number of patients treated, it seems that a better response could be assessed in 
whom where the drug reduce more relevantly sputum eosinophils [52]. It is interesting to underline 
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that the different action of these drugs (two blocking the cytokine and one its receptor),  lead to a 
common result but in a different way. Acting directly on the cytokine means modulate its action on 
eosinophils, usually normalizing the number at the peripheral level, as regards the benralizumab, 
having as its goal the receptor and a pro apoptotic action, we are going to eliminate this population. 
A direct action on the cell was found to be faster than that on the cytokine, but with the unknown 
factor of the suppression of a cell population. 
The available studies demonstrate that the different pharmacokinetic asset depends on the  
administration route, therefore the more appropriate administration is of relevance for each drug 
[71]. Furthermore, in a world where medicine is becoming increasingly personalized, where drugs 
are modelled on the immunological characteristics of patients, the pharmacokinetic and 
pharmacodynamic characteristics of biological drugs could play an important role in choosing one 
drug over another. To choose a drug at the moment we are rightly referring to the mechanism of 
action, but in the future could be also useful to consider also its pharmacokinetic and 
pharmacodynamic pattern in order to perform a medicine of precision [72].  
In addition, drugs that act on TH2 phenotype mechanisms will be able soon to respond to those 
patients when standard of care therapies are not sufficient. Finally, as a perspective, in allergic 
asthma the use of allergen-specific immunotherapy in combination with biologicals could be also 
considered, to expand the field of treatments of severe asthma [73]. 
9. EXPERT OPINION 
Starting with omalizumab then with mepolizumab currently with benralizumab and reslizumab and 
soon with dupilumab, additional therapeutic proposals are available for asthmatic allergic and 
hypereosinophilic patients, where the standard of care is ineffective. The pharmacokinetic and 
pharmacodynamic studies, so far performed, allowed to better define the mechanisms of action and 
characteristics of these drugs. However, not all drugs currently marketed have unravelled all doubts. 
Further observations are needed, particularly in real life, to evaluate the behaviour of such 
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molecules in relation, for instance, to the administration of other drugs [74]. A further point to be 
clarified is the one of the prescribing overlap, both among drugs with the same therapeutic target 
(anti IL-5 and IL-5r), and in allergic patients but with high blood eosinophils level.  
No direct head to head comparison with the mentioned drugs is available, however some data 
suggest that omalizumab is effective, regardless of eosinophil count [57], and that mepolizumab can 
control hypereosinophilic patients who had a poor response to omalizumab [75]. Benralizumab 
probably requires a separate discussion, since the different mechanism of action that involves also 
basophils CALIMA [63] and SIROCCO [64]. This latter molecule showed an efficacy substantially 
independent from IgE concentration [76]. No direct data are available in reslizumab trials. 
Dupilumab demonstrated its efficacy in allergic diseases as atopic dermatitis and also atopic 
patients. Due to the fact that all these drugs seems to be effective in some cases both in eosinophilic 
than in allergic patients, specific clinical trials will be needed in this group of patients with common 
prescription characteristics.  
Additionally, administration route could be a factor able to modify PK and PD and 
consequently, at least hypothetically, able to differentiate action of these drugs. Indeed, a IV 
administration could offer the advantage of avoiding presystemic degradation, allowing therefore to 
obtain a greater concentration of drug [46,77]. However, it is true that the route of administration 
SC proved to be equally effective and able to reduce the eosinophilic count, improving the 
symptoms of the patients, in the same way as with EV. 
The path of biological drugs for the control of severe asthma is certainly right but needs further 
investigation to better understand the mechanisms of these drugs. A greater understanding would 
also be very useful for targeting therapy, making it more and more personalized and precise, sewing 
it on the patient.  
 
Funding 
This paper was not funded.  
Ac
ce
pte
d M
an
us
cri
pt
 
 
Declaration of interest 
The authors have no relevant affiliations or financial involvement with any organization or entity 
with a financial interest in or financial conflict with the subject matter or materials discussed in the 
manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert 
testimony, grants or patents received or pending, or royalties.  
Acknowledgement: Assistance for this paper was provided by CIPRO (Centro Interprofessionale 
Pneumologico Ricerca Organizzazione) and ARMIA (Associazione Ricerca Malattie 
Immunologiche e Allergiche) Genova.  
 
 
 
  
Ac
ce
pte
d M
an
us
cri
pt
 
 
REFERENCES 
Papers of special note have been highlighted as: 
* of interest 
** of considerable interest 
1. Beasley R. The burden of asthma with specific reference to the United States. J Allergy Clin 
Immunol. 2002 May;109(5 Suppl):S482–9. 
2.   GINA gudelines of asthma. http://ginasthma.org/2017-gina-report-global-strategy-for-
asthma-245 management-and-prevention/. Accessed 02nd Sept 2018 
3.   Bagnasco D, Ferrando M, Caminati M, et al. Targeting interleukin-5 or interleukin-5Rα: 
safety considerations. Drug Saf (2017) 40(7):559–70.  
4.    Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS 243 guidelines on 
definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43: 343-73.  
** International definition of severe asthma and criteria to define it as uncontrolled 
5.   Godard P, Chanez P, Siraudin L, et al. Costs of asthma are correlated with severity: a 1-yr 
prospective study. Eur Respir J. 2002 Jan;19(1):61–7. 
6.   Caminati M, Pham DL, Bagnasco D, Canonica GW. Type 2 immunity in asthma. World 
Allergy Organ J. 2018 Jun 26;11(1):13.  
* An interesting review about Th2 mechanisms in asthma 
7.   Lombardi C, Savi E, Ridolo E, et al. Is allergic sensitization relevant in severe asthma? 
Which allergens may be culprit? World Allergy Organ J. 2017 Jan 6;10(1):2. 
Ac
ce
pte
d M
an
us
cri
pt
 
 
8.   De Ferrari L, Chiappori A, Bagnasco D, et al. Molecular phenotyping and biomarker 
development: are we on our way towards targeted therapy for severe asthma? Expert Rev Respir 
Med (2016) 10:9–38.  
9.   Wynn TA. Type 2 cytokines: mechanisms and therapeutic strategies. Nat Rev Immunol. 
2015;15(5):271–282. 
10.   Oliphant CJ, Barlow JL, McKenzie AN. Insights into the initiation of type 2 immune 
responses. Immunology. 2011;134(4):378–385 
11.   Chang TW, Wu PC, Hsu CL, Hung AF. Anti-IgE antibodies for the treatment of IgE 
mediated allergic diseases. Adv Immunol. 2007;93:63–119. 
12.   Luu M, Bardou M, Bonniaud P, Goirand F. Pharmacokinetics, pharmacodynamics and 
clinical efficacy of omalizumab for the treatment of asthma. Expert Opin Drug Metab Toxicol. 2016 
Dec;12(12):1503-1511. 
13.   Hendeles L, Sorkness CA. Anti-immunoglobulin E therapy with omalizumab for asthma. 
Ann Pharmacother. 2007 Sep;41(9):1397–410. 
14.   European Medicines Agency - Xolair - Product information. Available from: 
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Product_Information/human/000606/WC500057298.pdf 
15.   Food and Drug Administration – Xolair Available from: 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/omalgen062003LB.pdf 
16.   Bang LM, Plosker GL. Omalizumab: a review of its use in the management of allergic 
asthma. Treat Respir Med. 2004;3(3):183-99 
Ac
ce
pte
d M
an
us
cri
pt
 
 
17.   MacGlashan DW, Bochner BS, Adelman DC, et al. Down-regulation of Fc(epsilon)RI 
expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J 
Immunol Baltim Md 1950. 1997 Feb 1;158(3):1438–45. 
18.   Noga O, Hanf G, Kunkel G, Kleine-Tebbe J. Basophil histamine release decreases during 
omalizumab therapy in allergic asthmatics. Int Arch Allergy Immunol. 2008;146(1):66-70. 
19.   Dodig S, Richter D, Cepelak I, Benko B. Anti-IgE therapy with omalizumab in asthma and 
allergic rhinitis. Acta Pharm. 2005;55:123–138 
20.   Varricchi G, Bagnasco D, Borriello F, et al. Interleukin-5 pathway inhibition in the 
treatment of eosinophilic respiratory disorders: evidence and unmet needs. Curr Opin Allergy Clin 
Immunol (2016) 16(2):186–200. 
21.   Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe 
eosinophilic asthma. N Engl J Med 2014; 371:1198–1207 
22. Bagnasco D, Caminati M, Ferrando M, et al. Anti-IL-5 and IL-5Ra: Efficacy and Safety of 
New Therapeutic Strategies in Severe Uncontrolled Asthma. Biomed Res Int. 2018 Nov 
5;2018:5698212 
23. Schofield JP. An open, randomized, parallel group study to assess the bioavailability 
following administration at 3 subcutaneous sites and 1 intramuscular site relative to intravenous 
administration of single 250 mg doses of SB-240563 to healthy volunteers. Brentford: 
GlaxoSmithKline, 2002 (Data on file) 
24.   Choi MS, Dixit D, Bridgeman MB. Mepolizumab (Nucala) For Severe Eosinophilic 
Asthma. P T. 2016 Oct; 41(10): 619–622. 
25.   Waldmann TA, Strober W. Metabolism of immunoglobulins. Prog Allergy 1969; 13: 1-110 
Ac
ce
pte
d M
an
us
cri
pt
 
 
26.   Mould DR, Sweeney KR. The pharmacokinetics and pharmacodynamics of monoclonal 
antibodies-mechanistic modeling applied to drug development. Curr Opin Drug Discov Devel 2007; 
10 (1): 84-96 
27.   Smith D, Minthorn EA, Beerahee M. Pharmacokinetics and Pharmacodynamics of 
Mepolizumab, an Anti-Interleukin-5 Monoclonal Antibody Clin Pharmacokinet 2011; 50 (4): 215-
227 
28.   Leckie MJ, tenBrinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal 
antibody on eosinophils, airway hyper-responsiveness, and the late asthma response. Lancet 
2000;356:2144–2148  
** One of the first trial using anti IL-5 
29.   Pouliquen IJ, Kornmann O, Barton SV, et al. Characterization of the relationship between 
dose and blood eosinophil response following subcutaneous administration of mepolizumab. Int J 
Clin Pharmacol Ther. 2015 Dec;53(12):1015-27. 
30.   Freestone S. A double-blind, placebo controlled, parallel group study to assess the 
tolerability and pharmacokinetics of three 250 mg subcutaneous doses of SB-240563 in male and 
female patients with asthma. Brentford: Glaxo- SmithKline, 2001 (Data on file) 
31.   Ortega H, Yancey S, Cozens S. Pharmacokinetics and absolute bioavailability of 
mepolizumab following administration at subcutaneous and intramuscular sites. Clin Pharmacol 
Drug Dev. 2014 Jan;3(1):57-62 
32.   Freestone S. A double blind, placebo controlled, dose rising study to assess safety and 
pharmacokinetics of SB-240563 in male patients with mild asthma. Brentford: GlaxoSmithKline, 
1998 (Data on file) 
Ac
ce
pte
d M
an
us
cri
pt
 
 
33.   Flood-Page PT, Menzies-Gow AN, Kay AB, et al. Eosinophil’s role remains uncertain as 
anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 
2003; 167 (2): 199-204 
34.   Matera MG, Calzetta L, Rinaldi B, Cazzola M. Pharmacokinetic/pharmacodynamic drug 
evaluation of benralizumab for the treatment of asthma. Expert Opin Drug Metab Toxicol. 2017 
Sep;13(9):1007-1013 
** exhaustive review about PK and PD of anti IL-5R 
35.   Ghazi A, Trikha A, Calhoun WJ. Benralizumab - a humanized mAb to IL-5Rα with 
enhanced antibody-dependent cell-mediated cytotoxicity - a novel approach for the treatment of 
asthma. Expert Opin Biol Ther. 2012;12(1):113–118. 
36.   Passalacqua G, Matucci A, Vultaggio A, Bagnasco D, Mincarini M, Maggi E, et al. The 
safety of monoclonal antibodies in asthma. Expert Opin Drug Saf (2016) 15(8):1087–95. 
* interesting review about the safety of principal biologic antibodies to treat severe asthma 
37.   Broughton SE, Nero TL, Dhagat U, et al. The betac receptor family: structural insights and 
their functional implications. Cytokine 2015; 74:247–258. 
38.    Busse WW, Katial R, Gossage D, et al. Safety profile, pharmacokinetics, and biologic 
activity of MEDI-563, an anti-IL-5 receptor antibody, in a phase I study of subjects with mild 
asthma. J Allergy Clin Immunol. 2010;125(6):1237–1244. 
39. Pelaia C, Calabrese C, Vatrella A, et al. Benralizumab: From the Basic Mechanism of 
Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma. Biomed Res 
Int. 2018 May 10;2018:4839230 
Ac
ce
pte
d M
an
us
cri
pt
 
 
40.   Jin F, White W, Gossage D, et al. Multiple ascending subcutaneous (SC) dose study of 
MEDI-563: pharmacokinetics and immune response in adult asthmatics [abstract]. European 
Respiratory Society – 20th Annual Congress, Barcelona, Sept 18-22, 2010, P4553 
41.   Gossage D, Geba G, Gillen A, et al. A multiple ascending subcutaneous (SC) dose study of 
MEDI-563, a humanized anti-IL5Ra monoclonal antibody, in adult asthmatics [abstract]. European 
Respiratory Society – 20th Annual Congress, Barcelona, Sept 18-22, 2010, P1177 
42.   Wang B, Yan L, Yao Z, et al. Population pharmacokinetics and pharmacodynamics of 
benralizumab in healthy volunteers and patients with asthma. PT Pharmacometrics Syst Pharmacol. 
2017;6(4):249–257. 
43.   Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. 
Clin Pharmacokinet. 2010;49:633–659 
44.   Laviolette M, Gossage DL, Gauvreau G, et al. Effects of benralizumab on airway 
eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 
2013;132:1086–1096. 
45.   http://ir.tevapharm.com/mobile.view?c=73925&amp;v=203&amp;d=1&amp;id=2327641. 
46.   Matera MG, Rogliani P, Calzetta L, Cazzola M. Pharmacokinetic/pharmacodynamic 
profile of reslizumab in asthma. Expert Opin Drug Metab Toxicol. 2018 Feb;14(2):239-245 
47.   Deeks ED, Brusselle G. Reslizumab in eosinophilic asthma: a review. Drugs. 2017;77:777-
84 
48.   Jaworowicz D, Fiedler-Kelly J, Rabinovich-Guilatt L, et al. The steady-state 
pharmacokinetic (PK) profile across a range of patient body weight categories supports weight-
based dosing for intravenous (iv) reslizumab [abstract]. Am J Respir Crit Care Med. 
2016;193:A1389. 
Ac
ce
pte
d M
an
us
cri
pt
 
 
49.   Egan RW, Athwal D, Bodmer MW, et al. Effect of SCH55700, a humanized monoclonal 
antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivity. 
Arzneimittelforschung. 1999;49:779-90 
50.   Zhang J, Kuvelkar R, Murgolo NJ, et al. Mapping and characterization of the epitope(s) of 
Sch 55700, a humanized mAb, that inhibits human IL-5. Int Immunol. 1999;11:1935-44. 
51.   Kipps JC, O’Connor BJ, Langley SJ, et al. Effect of SCH55700, a humanized antihuman 
interleukin-5 antibody, in severe persistent asthma. Am J Respir Crit Care Med. 2003;167:1655-9. 
52.  Mukherjee M, Paramo FA, Kjarsgaard M, et al. Weight-adjusted intravenous reslizumab in 
severe asthma with inadequate response to fixed-dose subcutaneous mepolizumab. Am J Respir Crit 
Care Med. 2018;197(1):38-46 
53.   Passalacqua G, Mincarini M, Colombo D, et al. IL-13 and idiopathic pulmonary fibrosis: 
Possible links and new therapeutic strategies. Pulm Pharmacol Ther. 2017 Aug;45:95-100. 
54.   https://ec.europa.eu/health/documents/community-
register/2017/20170926138667/anx_138667_en.pdf 
55.   Wenzel S, Castro M, Corren J, et al. Dupilumab effi cacy and safety in adults with 
uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a 
long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-
ranging trial. Lancet 2016; 388: 31–44 
56.   Castro M, Corren J, Pavord ID, et al. Dupilumab Efficacy and Safety in Moderate-to-
Severe Uncontrolled Asthma. N Engl J Med. 2018 Jun 28;378(26):2486-2496 
57. Humbert M, Taillé C, Mala L, et al. Omalizumab effectiveness in patients with severe 
allergic asthma according to blood eosinophil count: the STELLAIR study. Eur Respir J. 2018 May 
10;51(5). 
Ac
ce
pte
d M
an
us
cri
pt
 
 
58. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized 
monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001 
Aug;108(2):184-90 
59. Solèr M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations 
and steroid requirement in allergic asthmatics. Eur Respir J. 2001 Aug;18(2):254-61. 
60. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma 
(DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012 Aug 
18;380(9842):651-9 
61. Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on 
health-related quality of life and markers of asthma control in severe eosinophilic asthma 
(MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b 
trial. Lancet Respir Med. 2017 May;5(5):390-400 
62. Bel EH, Wenzel SE, Thompson PJ, et al.  Oral glucocorticoid-sparing effect of 
mepolizumab in eosinophilic asthma. N. Engl. J. Med. 2014 371(13), 1189-97. 
63. FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α 
monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic 
asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016 Oct 
29;388(10056):2128-2141 
64. Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for 
patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting 
β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016 
Oct 29;388(10056):2115-2127 
Ac
ce
pte
d M
an
us
cri
pt
 
 
65. Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, et al. 
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from 
two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet 
Respir Med 2015. 3:355–66 
66. Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, et al. Reslizumab for poorly 
controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care 
Med (2011) 184:1125–32.  
67. Corren J, Weinstein S, Janka L, et al. Phase 3 Study of Reslizumab in Patients With Poorly 
Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts. Chest. 2016 
Oct;150(4):799-810. 
68. Bjermer L, Lemiere C, Maspero J, et al. Reslizumab for Inadequately Controlled Asthma 
With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study. Chest. 2016 
Oct;150(4):789-798  
69. Castro M, Corren J, Pavord ID, et al. Dupilumab Efficacy and Safety in Moderate-to-Severe 
Uncontrolled Asthma. N Engl J Med. 2018 Jun 28;378(26):2486-2496 
70. Rabe KF, Nair P, Brusselle G, et al. Efficacy and Safety of Dupilumab in Glucocorticoid-
Dependent Severe Asthma. N Engl J Med. 2018 Jun 28;378(26):2475-2485 
71. Matucci A, Vultaggio A, Danesi R.  The use of intravenous versus subcutaneous 
monoclonal antibodies in the treatment of severe asthma: a review . Respir Res. 2018 Aug 
16;19(1):154 
72. Morse BL, Kim RB. Is personalized medicine a dream or a reality? Crit Rev Clin Lab Sci. 
2015 Feb;52(1):1-11  
Ac
ce
pte
d M
an
us
cri
pt
 
 
73.   Lombardi C, Canonica GW, Passalacqua G. Allergen immunotherapy as add-on to biologic 
agents. Curr Opin Allergy Clin Immunol. 2018 Aug 24. doi: 10.1097/ACI.0000000000000479 
74. Bagnasco D, Milanese M, Rolla G, et al. Anti-IL-5 therapy in real life. The North-Western 
Italian experience 3 and comparison with the regulatory trials. WAOJ-D 2018;11:34 
75.   Galkin D, Liu MC, Chipps BE, et al. Efficacy and Safety of Mepolizumab in Uncontrolled 
Patients with Severe eosinophilic Asthma Following a Switch from Omalizumab (OSMO Study): 
Exacerbation and Safety Outcomes. https://doi.org/10.1016/j.jaci.2017.12.965 
76. Chipps BE, Newbold P, Hirsch I, et al. Benralizumab efficacy by atopy status and serum 
immunoglobulin E for patients with severe, uncontrolled asthma. Ann Allergy Asthma Immunol. 
2018 May; 120 (5): 504-511.e4 
77.   Casale TB, Pacou M, Mesana L, et al. Reslizumab Compared with Benralizumab in 
Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis. J 
Allergy Clin Immunol Pract. 2018 Sep 11. pii: S2213-2198(18)30576-2 
  
Ac
ce
pte
d M
an
us
cri
pt
 
 
Drug Dose Reference
s 
Bioavailabilit
y 
AUC Cmax CL Vss T1/2
Omalizumab 0.5 
mg/kg 
s.c 
[13,14] 62% n.a. n.a. 2.4 ± 1.1 
mL/Kg/da
y 
78 ±
32 
mL/K
g 
26
days 
Mepolizuma
b 
250 mg 
s.c  
[21] 75% 1,238 ± 228 µg d/
mL 
34.1–
38.2±7.3–
12.1mg/m
L 
1.9 to 3.3 
mL/day/k
g 
55 to
85 
mL/k
g 
11 -
26day
s 
Benralizuma
b 
0.03–3 
mg/kg 
i.v.  
25–200 
mg s.c.  
[38] 
 
 [40] 
n.a.
 
52.6% 
5 ± 2–775 ± 110
μg∗d/mL 
0.12 ± 0.071–1.2 ± 
0.11 mg day/mL 
1± 0.3–82
± 
18μg/mL 
1.2–14 
μg/mL 
7 ± 3–4 ± 
0.6 
mL/kg/da
y 
65 ±
28–
71 ± 
18 
mL/k
g 
7 ± 2–
16 ± 3 
days 
Reslizumab 3.0mg/k
g i.v.  
[48] n.a. 27.2 to 33.1
mg·h/mL 
86.7 to
105.33 
μg/mL 
≈ 7 mL/h ≈ 5 L ≈ 24
days 
Dupilumab 75-600 
mg s.c. 
[54] 64% 73.3±40.0 mcg/mL
to 79.9±41.4 
mcg/mL 
n.a. 0.126 
L/day 
4.6 L 3 – 7
days 
 
Legenda: AUC = area under the serum concentration–time curve, Cmax = maximum plasma concentrations, 
CL = clearance; Vss = volume of distribution at steady state; T ½ = elimination half life: n.a.= not available 
Table 1 
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Table 2 . Main results about efficacy and safety of MAbs in severe asthma 
Authors Exacerbations Other endpoints Common and serious adverse events 
OMALIZUMAB 
[57-59]  Exacerbations v.s. 
placebo 
Lower emergency visit 
rate (0.24 vs 0.43, 
P=0.038) 
ICS dose reduction 
≥50% (median 75% vs 
50%, p<0.001) and 
discontinuation (39.6% 
vs 19.1%, p<0.001), 
ICS dose reduction 
≥50% (median 79% vs 
55%, 
p<0 .001) and 
discontinuation (43% vs 
19%, p < 
0.01)  
Lower respiratory tract infections, 
nasopharyngitis, headache, sinusitis, influenza, 
cough, upper respiratory tract infection, injection 
site reactions 
Serious asthma exacerbations requiring 
hospitalization, urticarial, depression, 
appendicitis, flu-like syndrome, suspected 
eosinophilic granuloma of the skull, intestinal 
villous adenoma with dysplasia, 
infectious mononucleosis, squamous cell 
carcinoma of the face 
MEPOLIZUMAB 
[21, 60-62]  Exacerbations (53% s.c. 
MENSA, 32% SIRIUS, 
48% DREAM) 
 FEV1 (98 ml s.c. 
MENSA), no change in 
DREAM 
ACQ-5 improve 
MENSA, SIRIUS, no 
variation in DREAM 
Nasopharyngitis, upper respiratory tract 
infection and headache 
Incidence of 7 % in intra-venous group, 8 % in 
subcutaneous, 14 % placebo 
RESLIZUMAB 
[65-68]  Exacerbations (61%, 
73%) 
Improve QoL Worsening of asthma symptoms, upper 
respiratory tract infections, nasopharyngitis, 2 
anaphylactic reactions, pneumonia, worsening of 
asthma 
BENRALIZUMAB 
[63,64] Exacerbations (45 % in 
Q4W, 51 % in Q8W), (36 
% in Q4W 
28 % in Q8W) 
FEV1 (106  ml Q4W, 
159 ml Q8W), (125 ml 
Q4W, 116 ml Q8W) 
Nasopharyngitis, worsening of asthma, 
headache, dizziness, cough, pyrexia, bronchitis, 
anxiety, hyperhidrosis, injection site reaction 
,allergic granulomatous angioitis, panic attack, 
paraesthesia, injection-site 
erythema, urticarial, herpes zoster, chest pain, 
pyrexia, tachycardia and anxiety, uterine 
leiomyoma, erythema nodosum, thyroid storm 
DUPILUMAB 
[69,70]  asthma exacerbation 
(46%) 
FEV1 (+130 ml) 
change of ACQ5 score 
conjunctivitis, injection site reactions, and local 
herpes simplex infections, Nasopharyngitis, 
urinary tract infection, upper respiratory tract 
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Decrease OCS dose 
infection 
Hypereosinophilia 
  
 
